ACADIA Pharmaceuticals (MEX:ACAD) Stock Based Compensation: MXN1,015 Mil (TTM As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN362.00
GF Value MXN495.48
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Stock Based Compensation?

ACADIA Pharmaceuticals MEX:ACAD 73 Stock Based Compensation is MXN1,015 Mil as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN495.48 (Modestly Undervalued). The stock has 10 warning signs investors should review.

ACADIA Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2026 was MXN265 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,015 Mil.

ACADIA Pharmaceuticals Stock Based Compensation Related Terms

ACADIA Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Stock Based Compensation Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,305.00 1,329.65 1,127.45 1,398.35 938.73

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 232.81 270.01 241.78 238.31 265.05
MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,015 Mil.

What does a Stock Based Compensation of MXN1,015 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Stock Based Compensation of MXN1,015 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Stock Based Compensation too high?
ACADIA Pharmaceuticals' current Stock Based Compensation is MXN1,015 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Stock Based Compensation compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Stock Based Compensation of MXN1,015 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Stock Based Compensation is MXN1,015 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN495.48, compared to a current price of MXN362.00 — trading 26.9% below its estimated fair value. The current Stock Based Compensation is MXN1,015 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Stock Based Compensation is MXN1,015 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of MXN362.00 is trading 26.9% below its estimated GF Value™ of MXN495.48. GuruFocus considers ACADIA Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:ACAD:

  • Stock Based Compensation: MXN1,015 Mil
  • GF Value™: MXN495.48 vs. price of MXN362.00 (26.9% below fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN362.00
Price
MXN495.48
GF Value